STOCK TITAN
  1. Home
  2. News
  3. ABBV

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
Rhea-AI Summary
AbbVie to present new data on SKYRIZI® and RINVOQ® at UEG Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
News
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
Rhea-AI Summary
AbbVie completes acquisition of Mitokinin, a biotech company developing a potential treatment for Parkinson's Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
acquisition
-
News
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
Rhea-AI Summary
AbbVie, the Broad Institute of MIT and Harvard, and Calico Life Sciences have published in Nature their discovery of ABBV-CLS-484, a potential first-in-class cancer immunotherapy. The preclinical data shows that ABBV-CLS-484 enhances anti-tumor immunity by targeting tumor cells, suppressing their growth, and activating immune cell types. ABBV-CLS-484 is currently in a Phase 1 clinical trial for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
clinical trial
News
AbbVie to Host Third-Quarter 2023 Earnings Conference Call
Rhea-AI Summary
AbbVie to announce Q3 2023 financial results on October 27, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
conferences earnings
-
News
Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field
Rhea-AI Summary
Allergan Aesthetics partners with Girls Inc. for the fifth year, supporting Project Accelerate to address inequality in the workplace and promote leadership paths in STEM. Only 28% of women work in STEM fields, but being employed in a STEM field can lead to economic success. Girls Inc. aims to support young women in their educational attainment and careers in STEM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
partnership
-
News
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
Rhea-AI Summary
AbbVie's Phase 3 CANOVA study evaluating venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma did not significantly improve progression-free survival (PFS). However, the treatment showed improvement in median PFS of 9.9 months compared to 5.8 months with the study comparator pomalidomide and dexamethasone. Other secondary endpoints, such as overall response rate and rate of very good partial response or better, showed positive results. AbbVie will discuss the data with health authorities to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
clinical trial
News
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Rhea-AI Summary
AbbVie receives conditional marketing authorization for TEPKINLY in the EU for the treatment of relapsed or refractory DLBCL, with an overall response rate of 62% and a complete response rate of 39% in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
News
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence
Rhea-AI Summary
Allergan Aesthetics announces positive results from Phase 3 study on onabotulinumtoxinA for platysma prominence treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
clinical trial
-
News
AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"
Rhea-AI Summary
AbbVie opens public voting for the 2023 Thriving Undergraduate and Graduate Scholarships for students with cystic fibrosis (CF). Two deserving students will receive $25,000 each. Voting period is from now until September 27.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
News
AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
Rhea-AI Summary
AbbVie announces positive results from Phase 3 study comparing risankizumab to ustekinumab for Crohn's disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#28 Ranked by Market Cap
#2312 Ranked by Stock Gains
#932 Ranked by Dividends

ABBV Stock Data

287.80B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.